534 related articles for article (PubMed ID: 8772689)
1. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
2. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study.
Vantrimpont P; Rouleau JL; Ciampi A; Harel F; de Champlain J; Bichet D; Moyé LA; Pfeffer M
Eur Heart J; 1998 Oct; 19(10):1552-63. PubMed ID: 9820995
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
[TBL] [Abstract][Full Text] [Related]
4. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
Stanek B; Frey B; Hülsmann M; Berger R; Sturm B; Strametz-Juranek J; Bergler-Klein J; Moser P; Bojic A; Hartter E; Pacher R
J Am Coll Cardiol; 2001 Aug; 38(2):436-42. PubMed ID: 11499735
[TBL] [Abstract][Full Text] [Related]
5. Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.
Patten RD; Kronenberg MW; Benedict CR; Udelson JE; Kinan D; Stewart D; Yusuf S; Smith JJ; Kilcoyne L; Dolan N; Edens TR; Metherall J; Konstam MA
Am Heart J; 1997 Jul; 134(1):37-43. PubMed ID: 9266781
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Francis GS; Shelton B; Johnstone DE; Kubo SH; Kirlin P; Nicklas J; Liang CS; Konstam MA; Greenberg B
Am J Cardiol; 1995 Jun; 75(16):1151-7. PubMed ID: 7762503
[TBL] [Abstract][Full Text] [Related]
7. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
8. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators.
Benedict CR; Weiner DH; Johnstone DE; Bourassa MG; Ghali JK; Nicklas J; Kirlin P; Greenberg B; Quinones MA; Yusuf S
J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):146A-153A. PubMed ID: 8376686
[TBL] [Abstract][Full Text] [Related]
9. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Sigurdsson A; Swedberg K
Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
[TBL] [Abstract][Full Text] [Related]
10. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.
Benedict CR; Johnstone DE; Weiner DH; Bourassa MG; Bittner V; Kay R; Kirlin P; Greenberg B; Kohn RM; Nicklas JM
J Am Coll Cardiol; 1994 May; 23(6):1410-20. PubMed ID: 7909822
[TBL] [Abstract][Full Text] [Related]
11. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
Sigurdsson A
Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
[TBL] [Abstract][Full Text] [Related]
12. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
[TBL] [Abstract][Full Text] [Related]
13. Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
Smith RF; Germanson T; Judd D; Wong M; Ziesche S; Anand IS; Taylor WR; Cohn JN
J Card Fail; 2000 Jun; 6(2):97-107. PubMed ID: 10908083
[TBL] [Abstract][Full Text] [Related]
14. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.
Konstam V; Salem D; Pouleur H; Kostis J; Gorkin L; Shumaker S; Mottard I; Woods P; Konstam MA; Yusuf S
Am J Cardiol; 1996 Oct; 78(8):890-5. PubMed ID: 8888661
[TBL] [Abstract][Full Text] [Related]
15. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
[TBL] [Abstract][Full Text] [Related]
16. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
[TBL] [Abstract][Full Text] [Related]
17. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; Macmahon S; Ikram H; Sharpe N; Espiner EA; Frampton C; Yandle TG
Circulation; 1999 Feb; 99(6):786-92. PubMed ID: 9989964
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of plasma renin activity in heart failure.
Vergaro G; Emdin M; Iervasi A; Zyw L; Gabutti A; Poletti R; Mammini C; Giannoni A; Fontana M; Passino C
Am J Cardiol; 2011 Jul; 108(2):246-51. PubMed ID: 21545993
[TBL] [Abstract][Full Text] [Related]
19. Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study.
Sigurdsson A; Eriksson SV; Hall C; Kahan T; Swedberg K
Eur J Heart Fail; 2001 Jan; 3(1):69-78. PubMed ID: 11163738
[TBL] [Abstract][Full Text] [Related]
20. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
Omland T; Aakvaag A; Bonarjee VV; Caidahl K; Lie RT; Nilsen DW; Sundsfjord JA; Dickstein K
Circulation; 1996 Jun; 93(11):1963-9. PubMed ID: 8640969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
